Healthcare Industry News: joint replacement
News Release - July 12, 2006
Biomet Announces Senior Management ChangesWARSAW, Ind.--(HSMN NewsFeed)--July 12, 2006--Biomet, Inc. (NASDAQ:BMET ) today announced that Charles E. Niemier has been appointed as President of EBI's operations following the resignation of Bart J. Doedens, M.D., former President of EBI, who has decided to pursue other interests. Mr. Niemier has been a member of senior management and the Board of Directors of Biomet for more than 25 years and has served in a variety of operational roles with Biomet during his tenure including Chief Financial Officer and, more recently, Chief Operating Officer - International Operations. Additionally, Robert Phelps has been promoted to Vice President-Sales at EBI. Mr. Phelps has over 25 years of experience in the orthopedic industry with Johnson & Johnson and most recently with Biomet as its Area Vice President, Northeast/Mid-Atlantic Sales. Joe Milano has joined EBI as its Vice President, Finance and Administration. Mr. Milano was most recently Executive Vice President and CFO for Aircast.
Biomet's Interim President and Chief Executive Officer, Daniel P. Hann, commented, "We are pleased to announce the appointment of Mr. Niemier as President of EBI. We are confident that Mr. Niemier will provide the leadership capabilities necessary to position EBI as a leader in the spinal and fixation market places, and improve our leadership position in electrical stimulation. Additionally, the senior management team at EBI has been significantly strengthened with the additions of both Mr. Phelps and Mr. Milano in the key areas of sales management and finance."
Biomet, Inc. and its subsidiaries design, manufacture and market products used primarily by musculoskeletal medical specialists in both surgical and non-surgical therapy. The Company's product portfolio encompasses reconstructive products, including orthopedic joint replacement devices, bone cements and accessories, and dental reconstructive implants; fixation products, including electrical bone growth stimulators, internal and external orthopedic fixation devices, craniomaxillofacial implants and bone substitute materials; spinal products, including spinal stimulation devices, spinal hardware and orthobiologics; and other products, such as arthroscopy products and softgoods and bracing products. Headquartered in Warsaw, Indiana, Biomet and its subsidiaries currently distribute products in more than 100 countries.
For further information contact Greg W. Sasso, Senior Vice President, Corporate Development and Communications at (574) 372-1528 or Barbara Goslee, Manager, Corporate Communications at (574) 372-1514.
This press release contains certain statements that are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, such as the Company's estimated results. Although the Company believes that the assumptions, on which the forward-looking statements contained herein are based, are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or non-occurrence of future events. In particular, the Company cautions the reader that the results discussed herein are only estimates, and that new or additional information could cause such results to differ materially. There can be no assurance that the forward-looking statements contained in this press release will prove to be accurate. Some of the factors that could cause actual results to differ from those contained in forward-looking statements made in this press release include the success of the Company's principal product lines, the Company's ability to develop and market new products and technologies in a timely manner, government regulation, currency exchange rate fluctuations, reimbursements from third party payors, litigation, revenue and earnings estimates, and other risk factors as set forth from time to time in the Company's filings with the SEC. The inclusion of a forward-looking statement herein should not be regarded as a representation by the Company that the Company's objectives will be achieved. The Company undertakes no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
All of Biomet's financial information may be obtained on our website at www.biomet.com or you may contact us by e-mail at email@example.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsZimmer Biomet and Hospital for Special Surgery (HSS) Partner to Advance Innovation on mymobility(R) with Apple Watch(R) Remote Care Management System
Zimmer Biomet Completes Acquisition of A&E Medical Corporation
Israeli Pain Monitoring Startup Medasense Raises $18M in Series C Round